Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma: an Open-label, Single Arm, Phase II Trial

Trial Profile

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma: an Open-label, Single Arm, Phase II Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Decitabine (Primary) ; Tucidinostat (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 08 Jun 2021 Results (n=19) assessing safety and efficacy of the combination of decitabine-plus-camrelizumab and chidamide in decitabine-plus-camrelizumab resistant classical Hodgkin lymphoma patients, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
  • 12 Aug 2020 Planned number of patients changed from 280 to 100.
  • 23 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top